Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (221-230 of 337) with videos related to

Pageof 34
Sort By:
Vaccine|September 10, 2025
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trialDavid J Diemert, Daniel S Graciaa, Bo Zhang, et al.
Nature Communications|February 22, 2019
Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccineSlim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, et al.
Plos Computational Biology|April 2, 2019
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence featuresCraig A Magaret, David C Benkeser, Brian D Williamson, et al.
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.
Science Translational Medicine|November 22, 2019
Antigenic competition in CD4<sup>+</sup> T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trialEsper G Kallas, Nicole A Grunenberg, Chenchen Yu, et al.
Plos One|September 2, 2016
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African ParticipantsGavin Churchyard, Koleka Mlisana, Shelly Karuna, et al.
Scientific Reports|February 9, 2020
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine RegimensXiaoying Shen, Fatima Laher, Zoe Moodie, et al.
Cell Host & Microbe|September 13, 2019
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV ChallengeAmarendra Pegu, Bhavesh Borate, Yunda Huang, et al.
JAMA|August 15, 2006
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi StudyIbou Thior, Shahin Lockman, Laura M Smeaton, et al.
Journal of Virology|January 16, 2025
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistancePaula Cohen, Bronwen E Lambson, Nonhlanhla N Mkhize, et al.
Pageof 34

Showing results (221-230 of 337) with videos related to

Sort By:
Pageof 34
Vaccine|September 10, 2025
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trialDavid J Diemert, Daniel S Graciaa, Bo Zhang, et al.
Nature Communications|February 22, 2019
Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccineSlim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, et al.
Plos Computational Biology|April 2, 2019
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence featuresCraig A Magaret, David C Benkeser, Brian D Williamson, et al.
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.
Science Translational Medicine|November 22, 2019
Antigenic competition in CD4<sup>+</sup> T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trialEsper G Kallas, Nicole A Grunenberg, Chenchen Yu, et al.
Plos One|September 2, 2016
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African ParticipantsGavin Churchyard, Koleka Mlisana, Shelly Karuna, et al.
Scientific Reports|February 9, 2020
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine RegimensXiaoying Shen, Fatima Laher, Zoe Moodie, et al.
Cell Host & Microbe|September 13, 2019
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV ChallengeAmarendra Pegu, Bhavesh Borate, Yunda Huang, et al.
JAMA|August 15, 2006
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi StudyIbou Thior, Shahin Lockman, Laura M Smeaton, et al.
Journal of Virology|January 16, 2025
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistancePaula Cohen, Bronwen E Lambson, Nonhlanhla N Mkhize, et al.
Pageof 34